U.S. Markets open in 5 hrs 21 mins

Why Amarin Stock Is Tanking Today

George Budwell, The Motley Fool

What happened

Shares of Amarin (NASDAQ: AMRN) are down by a whopping 16.7% as of 12:03 p.m. EDT on Friday. The drugmaker's stock is getting pummeled in response to the news that the Food and Drug Administration (FDA) has indeed decided to convene an advisory committee meeting to discuss the company's proposed label expansion for the prescription omega-3 pill Vascepa.

A man holding his hand to his forehand with a look of shock on his face. A downward trending chart sits in the background.

So what

Last week, Amarin's management noted that an advisory committee meeting was no longer likely in its view, given that the drug's Prescription Drug User Fee Act (PDUFA) goal date of Sept. 28 was less than two months away. So it's not entirely surprising that some investors are heading for the exits in the wake of this unexpected regulatory update.

Now what

Vascepa's advisory committee meeting is tentatively scheduled for Nov. 14, 2019, according to Amarin's press release. The FDA is therefore expected to extend Vascepa's regulatory timeline beyond the original Sept. 28 PDUFA date. That's not the end of the world, so long as the FDA does eventually green light Vascepa's new label.

Why is the FDA holding an advisory committee meeting? While the company didn't release any details at this early juncture, the most likely reason is the mineral oil placebo issue.

In Vascepa's large cardiovascular outcomes trial known as Reduce-It, patients in the placebo arm reportedly experienced a noteworthy increase in bad cholesterol levels, which may have exaggerated Vascepa's observed cardio-protective benefits to some degree. On the plus side, this non-inert placebo issue shouldn't turn out to be a showstopper, meaning that bargain hunters may want to take advantage of this sizable drop in Amarin's stock.

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

This article was originally published on Fool.com